Delisting risk
ACXP · NASDAQ · Biotechnology

Acurx Pharmaceuticals (ACXP)

Developing selective-spectrum antibiotics for C. difficile and other Gram-positive infections.

$1.42
Pre-market−0.02 (−1.05%)
At close$1.44(+2.50%)

Something off on this page? Send us feedback.

Next report
Nov 11, 2026
in 69 days
EPS estimate
−$0.45
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.16−$2.20−$1.89−$1.23−$0.31−$0.62−$0.53Pending
Estimate−$0.18−$0.15−$2.00−$1.61−$1.01−$0.59−$0.38−$0.45
Surprise+11.1%−1,366.7%+5.5%+23.6%+69.3%−5.1%−40.7%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
ReportedPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.45
Aug 2026−$0.38−$0.53−40.7%
May 2026−$0.59−$0.62−5.1%
Mar 2026−$1.01−$0.31+69.3%
Nov 2025−$1.61−$1.23+23.6%

The latest year is open to everyone — the 22 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
Jun 2021
Mar 2021
Sep 2020
Jun 2020
Mar 2020
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 11, 2026−$0.45
Aug 14, 2026−$0.38−$0.53−40.7%−5.4%
May 12, 2026−$0.59−$0.62−5.1%−2.9%
Mar 13, 2026−$1.01−$0.31+69.3%+24.0%
Nov 12, 2025−$1.61−$1.23+23.6%−4.8%

The latest year is open to everyone — the 22 quarters behind it read with an account.

Sign in
Aug 11, 2025
May 12, 2025
Mar 17, 2025
Nov 12, 2024
Aug 9, 2024
May 14, 2024
Mar 15, 2024
Nov 13, 2023
Aug 14, 2023
May 12, 2023
Mar 16, 2023
Nov 14, 2022
Aug 15, 2022
May 11, 2022
Mar 17, 2022
Nov 12, 2021
Aug 16, 2021
Jun 28, 2021
Mar 31, 2021
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020